about
Subversion of innate defenses by the interplay between DENV and pre-existing enhancing antibodies: TLRs signaling collapseNovel hormone-regulated genes in visceral adipose tissue: cloning and identification of proinflammatory cytokine-like mouse and human MEDA-7: implications for obesity, insulin resistance and the metabolic syndromeBiochemical and Functional Insights into the Integrated Regulation of Innate Immune Cell Responses by Teleost Leukocyte Immune-Type ReceptorsVesicular trafficking and signaling for cytokine and chemokine secretion in mast cellsSiglecs and immune regulationSoluble fibrinogen like protein 2 (sFGL2), the novel effector molecule for immunoregulationControl of cytokine production by human fc gamma receptors: implications for pathogen defense and autoimmunityDendritic cell-bound IgE functions to restrain allergic inflammation at mucosal sitesPhosphorylation site dynamics of early T-cell receptor signalingLILRA2 selectively modulates LPS-mediated cytokine production and inhibits phagocytosis by monocytesIntravenous immunoglobulins modulate neutrophil activation and vascular injury through FcγRIII and SHP-1.Contribution of Human FcγRs to Disease with Evidence from Human Polymorphisms and Transgenic Animal StudiesSelective antibody intervention of Toll-like receptor 4 activation through Fc γ receptor tethering.Shifting FcγRIIA-ITAM from activation to inhibitory configuration ameliorates arthritisThe human immunoglobulin A Fc receptor FcαRI: a multifaceted regulator of mucosal immunity.Regulation of human osteoclast development by dendritic cell-specific transmembrane protein (DC-STAMP).The conundrum of inhibitory signaling by ITAM-containing immunoreceptors: potential molecular mechanisms.Engagement of Siglec-7 receptor induces a pro-inflammatory response selectively in monocytes.The era of the immunoglobulin A Fc receptor FcαRI; its function and potential as target in disease.The unexplored roles of human serum IgA.The immunoreceptor adapter protein DAP12 suppresses B lymphocyte-driven adaptive immune responses.Negative regulation of glial engulfment activity by Draper terminates glial responses to axon injury.IgG4 can induce an M2-like phenotype in human monocyte-derived macrophages through FcγRI.Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?Host Immune Responses in HIV-1 Infection: The Emerging Pathogenic Role of Siglecs and Their Clinical Correlates.Modulation of CTLA-4 and GITR for cancer immunotherapy.Stimulus-secretion coupling by high-affinity IgE receptor: new developments.Immunoglobulin A: A next generation of therapeutic antibodies?Molecular insights for optimizing T cell receptor specificity against cancer.ITIM-dependent negative signaling pathways for the control of cell-mediated xenogeneic immune responses.The function of Fcγ receptors in dendritic cells and macrophages.Role of FcγRIIIA (CD16) in IVIg-mediated anti-inflammatory function.Type I and type II Fc receptors regulate innate and adaptive immunity.Signalling versatility following self and non-self sensing by myeloid C-type lectin receptors.Regulation of fc receptor endocytic trafficking by ubiquitination.The MS4A family: counting past 1, 2 and 3.Mouse and human FcR effector functions.The many faces of FcγRI: implications for therapeutic antibody function.The high-affinity receptor for IgG, FcγRI, of humans and non-human primates.Cross-talk between pathogen recognizing Toll-like receptors and immunoglobulin Fc receptors in immunity.
P2860
Q21144516-DEB06A78-0A24-484A-BD0A-362046C8F85BQ24306922-12FFF75B-926B-4232-ACB2-6D5787CA9BEBQ26752544-49DE18AC-C274-49E3-B205-2F97C062CDDBQ26851822-8A2D08AC-3C3D-4378-A6F4-76E599F9BA03Q26992091-5DD623A5-F433-436B-B899-CF102605779BQ28080245-DF9FD175-9B36-4BCC-AD6B-B3E9BCB84000Q28085328-5370F059-94B0-4822-B82E-A8028F2C2E57Q28390013-A2F0E9E4-A340-4595-B62B-B0BB74EE41D2Q28542511-287B9F08-31C4-474C-B616-03C93C17573DQ28730830-512A6E8B-93E4-47C2-831A-FAB88CF736D9Q30514056-39D8E58A-68E0-43E5-8E5B-752C2CF1F5A8Q33686907-C94A7BB8-AFB1-4CFB-8E8D-CD63FEFD4ABAQ34075883-2377E6BE-A54A-4C65-A162-90CC37BCF530Q34117596-E1A8FAC3-B13D-4C94-8024-7C45FA84327FQ34218284-A1A1B585-B41C-45D3-A92D-55F675BA324EQ34222920-C17B58AA-0685-40F9-9C92-59A372177DCDQ34388481-DCE2D858-9555-435E-9966-3BD14DD54A98Q34430165-07780F6B-4A57-46AC-ACB5-5902B2CAE23FQ34499286-ACB8D443-0FED-4532-A1FC-A1E71B340410Q34589997-A3E24592-8941-4110-A690-E6A31D6CBD4DQ35144618-BE24AADA-908C-4789-A258-4E76AF76E049Q35916532-1FA4A376-F12F-4D42-BBA2-C69D52DB778DQ36213225-1803C95E-547E-46BC-B52A-BA740AB20FE8Q37114367-A450DBCE-EAEB-462B-B891-CF1790083164Q37716750-EBF284DD-E6C4-4F30-9F62-CA5ED67D7879Q37766483-C924989B-07EC-40A6-B193-BC21FD9DE27CQ37790062-F447C7CF-73B9-44F7-889C-4DDB4FF03EABQ37892323-FAF5C27D-CBE2-4767-975C-D0DA8679BBBAQ38117139-979BF1B6-D8C5-448D-AE5B-866D4CBB46D0Q38130755-00F92A6C-F53E-4FA5-9095-0138AC0BF244Q38180345-08885F30-36BF-42DA-8430-2FC6BAC8A666Q38204293-779A9B97-B5BD-48D5-B29F-7D695C7A4471Q38232105-8F951569-E117-491E-988E-C16F500B4E8BQ38255641-4489C460-A26E-4BC0-B392-ADFF554009C1Q38256371-9FBAB517-A1B4-41BC-BC85-2A1BB61E0D62Q38401877-60476764-968A-4DB2-ACB3-1CB2BE786CC7Q38615349-A6404C46-5C0A-4B90-B9CD-1AF4A39AE0A1Q38615362-E3CDF31C-F542-4EE4-B083-E2B862A7087AQ38615370-5CDB3516-0326-4638-BADE-1348DF97CAD4Q38615394-171D73D9-9CBF-4F93-99B2-CA3973B0B021
P2860
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Inhibitory ITAMs as novel regulators of immunity.
@en
Inhibitory ITAMs as novel regulators of immunity.
@nl
type
label
Inhibitory ITAMs as novel regulators of immunity.
@en
Inhibitory ITAMs as novel regulators of immunity.
@nl
prefLabel
Inhibitory ITAMs as novel regulators of immunity.
@en
Inhibitory ITAMs as novel regulators of immunity.
@nl
P2860
P50
P1476
Inhibitory ITAMs as novel regulators of immunity
@en
P2093
Pierre Launay
P2860
P356
10.1111/J.1600-065X.2009.00832.X
P577
2009-11-01T00:00:00Z